24-Hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: Comparison with placebo and formoterol

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 463-470

  Bauwens, Olivier ^a   Ninane, Vincent ^a   Van De Maele, Boudewijn ^b   Firth, Roz ^c   Dong, Fang ^d   Owen, Roger ^c   Higgins, Mark ^c  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b Pneumologie   (Belgium)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bronchodilation; Chronic obstructive pulmonary disease; FEV1; Formoterol; Indacaterol; Single dose

Indexed keywords

AEROLIZER; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; GLUCOSE; INDACATEROL; PLACEBO; POTASSIUM; SALBUTAMOL; SHORT ACTING DRUG; UNCLASSIFIED DRUG; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; POWDER INHALER; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AREA UNDER THE CURVE; MIDDLE AGED; VITAL CAPACITY;

ADULT; AGED; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MIDDLE AGED; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; VITAL CAPACITY;

EID: 64249171524     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802675096     Document Type: Article

References (24)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006;27:397-412 (Pubitemid 43180921)
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3: e442. doi:10.1371/journal.pmed. 0030442
3. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007 (based on an April 1998 NHLBI/WHO Workshop). Available at: http://goldcopd.com [Last accessed 13 May 2008]
4. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62. Erratum in: Thorax 2007; 62:191 (Pubitemid 44570305)
5. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-784 (Pubitemid 32881913)
6. 2-agonist, provides sustained 24-hour bronchodilation in asthma. Eur Respir J 2007;29:871-878
7. 2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-749
8. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-1044
9. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005 (based on an April 1998 NHLBI/WHO Workshop). Available at: http://goldcopd.com [Last accessed 13 May 2008]
10. Mueller S, Haeberlin B, Edge S. Comparison of performance characteristics for Foradil Aerolizer® and Foradil Concept1 (a new single dose dry powder inhaler) at different test flow rates. Respir Drug Deliv 2008;3:675-678 [RDD Online, Richmond, VA, USA]
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338 (Pubitemid 41079078)
12. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-1283
13. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007;81:108-113 (Pubitemid 46050875)
14. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005. Available at: http://www.fda.gov/cder/guidance/index.htm [Last accessed 13 May 2008]
15. Wise RA, Connett J, Kurnow K, et al. Selection of spirometric measurements in a clinical trial, the Lung Health Study. Am J Respir Crit Care Med 1995;151:675-681
16. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111-124 (Pubitemid 40776231)
17. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-838
18. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007;101:1895-1902 (Pubitemid 47163538)
19. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110(6 Suppl):S322-8
20. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-2321 (Pubitemid 38796452)
21. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646 (Pubitemid 41507622)
22. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada. Ann Epidemiol 2006;16:63-70
23. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study. Respir Med 2007;101:2065-2075 (Pubitemid 47336870)
24. 2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day study. Ann Allergy Asthma Immunol 2007;99:555-561